Amit Khera, MD, MSc, FACC, FAHA, FASPC
Dr. Khera is a President of the American Society for Preventive Cardiology and Professor of Medicine at the University of Texas, Southwestern Medical School in Dallas, Texas where he serves as Director of the Preventive Cardiology Section, and holder of the Dallas Heart Ball Chair in Hypertension and Heart Disease. His clinical and research interests include the primary and secondary prevention of coronary artery disease, focusing on risk assessment and risk factor modification in those with premature and familial disease.
Dr. Khera received his undergraduate degree in American History from the University of Pennsylvania, with magna cum laude honors. He obtained his medical degree from Baylor College of Medicine where he served as class president and was inducted into the Alpha Omega Alpha honor medical society. He completed an Internal Medicine Residency at Brigham and Women’s Hospital, Harvard Medical School, followed by a Cardiology Fellowship at the University of Texas, Southwestern Medical Center. He also completed his Masters degree in Epidemiology at the Harvard School of Public Health.
He has published over 100 articles in the field of preventive cardiology and has served on numerous local and national committee and leadership roles for the American Heart Association (AHA), American College of Cardiology, and American Society for Preventive Cardiology (ASPC).
Peter P. Toth, MD, PhD, FASPC
Dr. Toth received his B.A. in Biochemistry from Princeton University and a Ph.D. in Biochemistry from Michigan State University. He graduated from Wayne State University School of Medicine and completed residency training in Family Medicine at the University of Iowa Hospitals and Clinics. He is a member of Alpha Omega Alpha and Sigma Xi, and is a past President of the National Lipid Association. Dr. Toth is President of the American Board of Clinical Lipidology and a member of the board of the American Society of Preventive Cardiology.
Dr. Toth has authored and coauthored over four hundred publications in medical and scientific journals and textbooks. He is Editor-in-Chief of the Year in Lipid Disorders (Atlas Publishing, Oxford, UK) and an Associate Editor for the Year Book of Endocrinology (Elsevier, New York). He is coeditor of nine textbooks, including the Family Practice Handbook, Comprehensive Management of High Risk Cardiovascular Patients, Therapeutic Lipidology, Current Controversies in Dyslipidemia Management, Practical Lipid Management, Comprehensive Cardiovascular Care in the Primary Care Setting, Clinical Challenges in Hypertension vols I and II, Cardiac Lipoglucotoxicity, Lipoproteins in Diabetes Mellitus. He has lectured on many topics in cardiovascular medicine throughout the world.
Martha Gulati, MD, MS, FACC, FAHA
Martha Gulati, MD, MS, FACC, FAHA is a Professor of Medicine and the chief of cardiology at the University of Arizona (Phoenix). She held the Sarah Ross Soter Chair in Women’s Cardiovascular Health and was the Section Director for Women’s Cardiovascular Health and Preventive Cardiology at The Ohio State University until 2015. She is the author of the best-seller, “Saving Women’s Hearts”. She is the Editor- in-Chief of the American College of Cardiology “CardioSmart”, the patient education and empowerment initiative.
Her exceptional commitment to the study of women and cardiac diseases has won her numerous awards and distinctions, including being named by Crain’s Chicago Business as one of Chicago’s “Top 40 under 40,” a list that honors 40 outstanding individuals who have made a major impact in their respective industries before the age of 40. In 2011, she received the first CREDO (Coalition to Reduce Racial and Ethnic Disparities in Cardiovascular Outcomes) Award from the American College of Cardiology that was given to honor her contributions to improve cardiovascular healthcare of women patients. In 2012, she was awarded the National Red Dress Award for her efforts in raising awareness of heart disease in women and advancing research in this field.
Dr. Gulati is passionate about the study of women and heart disease and prevention of heart disease. She is the principal investigator of the St. James Women Take Heart Project, a study examining cardiac risk factors in women, which set new standards for women’s fitness levels and heart rate response to exercise in women. She also is a co- investigator on the Women Ischemic Syndrome Evaluation (WISE) and previously served as a co-investigator on the Women’s Health Initiative (WHI).
She is a member of numerous advisory boards and societies, including the American Heart Association (AHA), the American College of Cardiology and the American Society of Preventive Cardiology (ASPC). She serves on the board of the ASPC, the Phoenix chapter of the American Heart Association and the board of WomenHeart. She has published articles in peer-reviewed publications, including The New England Journal of Medicine, Circulation, and Journal of the American Medical Association (JAMA). Her research has been featured in hundreds of newspapers across the world, including The New York Times and USA Today. She has also been featured on Oprah and been feature on CBS National News, The Today Show, Canada AM, in addition to many others. She recently was listed on the Marquis 2018 Who’s Who in America, Who’s Who in the World, and Who’s Who in American Women.
Dr. Gulati completed medical school at the University of Toronto, Canada. She went on to complete her internship, residency, and cardiology fellowship at the University of Chicago. She received a Master in Science at the University of Chicago and is a fellow of the American College of Cardiology and the American Heart Association. She is board certified in cardiovascular disease.
Michael Shapiro, DO, FASPC
Michael Shapiro is the inaugural Fred M. Parrish Professor of Cardiology and Molecular Medicine at Wake Forest University where he is on faculty in the Section of Cardiovascular Medicine. After completing a cardiology fellowship, Michael spent two additional years in a clinical and research fellowship focused on advanced cardiovascular imaging at Massachusetts General Hospital/Harvard Medical School. After training, he was on faculty in the Knight Cardiovascular Institute at Oregon Health & Science University. He served as Director of Atherosclerosis Imaging and Associate Director of the Center for Preventive Cardiology. In 2019, he transitioned to Wake Forest University where he serves as the Director of the Center for Prevention of Cardiovascular Disease and the Co-Director of the NIH T32 Cardiovascular Disease Epidemiology and Prevention Research Fellowship Program.
Michael's clinical interests focus on genetic and acquired disorders of cholesterol and triglycerides, atherosclerosis Imaging, genetic predisposition to early myocardial infarction, and cardiovascular risk assessment in apparently healthy individuals. Michael has published extensively in the areas of atherosclerosis imaging, lipid disorders, and preventive cardiology. His current investigative research focuses on PCSK9 physiology and its impact on lipoprotein metabolism. Other areas of research include metabolomics of atherosclerosis, development and validation of automated quantification of breast arterial calcification as a means to refine cardiovascular risk estimation in women, and implementation of machine learning algorithms to identify individuals with familial hypercholesterolemia. He is an established Multiethnic Study of Atherosclerosis and Diabetes Heart Study investigator. He also serves as a principal investigator on numerous clinical trials testing novel lipid modulating therapeutics. Michael is a member of numerous boards and national committees related to preventive cardiology, familial hypercholesterolemia, and lipid disorders.
Seth J. Baum, MD, FASPC
Dr. Seth J. Baum, a graduate of Columbia College and Columbia College of Physicians and Surgeons, completed training in Internal Medicine, Cardiology, Interventional Cardiology, and Electrophysiology. He has directed and founded multiple Cardiac Catheterization and Electrophysiology laboratories. Dr. Baum has worked extensively in Integrative Cardiology, directing the Boca Raton division of Harvard’s Mind/Body Medicine Institute.
Dr. Baum is a fellow of the American College of Cardiology, the American Heart Association, the American College of Preventive Medicine, the National Lipid Association, and the American Society for Preventive Cardiology. He is a Founding Physician/Scientist Member of the Society for Cardiovascular CT and is board certified in Cardiovascular CT. Dr. Baum served as treasurer of the International Society for the Study of Fatty Acids and Lipids. He founded and directs the Women’s Preventive Cardiology program at Boca Raton Regional Hospital. He is the President of the American Society for Preventive Cardiology (ASPC). Annually, Dr. Baum chairs the ASPC’s Conference on CVD Prevention. Dr. Baum is the Secretary/Treasurer of the Board of Directors of the FH Foundation. He sits on the American Heart Association’s Council for Epidemiology and Prevention, the Interdisciplinary Council for Prevention, and the Prevention Science Committee. He has written numerous peer reviewed papers as well as two books, The Total Guide to a Healthy Heart, and Age Strong, Live Long; Lessons from my Patients. In 2013 he was awarded Cleveland Heart Lab’s “Heart Award” for lifelong dedication to Preventive Medicine. Dr. Baum is the Founder and Chief Medical Officer of Excel Medical Clinical Trials, LLC, a consortium of clinicians dedicated to the safe and professional conduct of high-level scientific trials.
Associate Affiliate Professor of Medicine at FAU Medical School, Dr. Baum has a practice in Boca Raton, Florida that is devoted solely to Clinical Lipidology - he is board certified by the American Board of Clinical Lipidology - and Cardiovascular Disease Prevention. Dr. Baum also founded and directs the only lipoprotein apheresis program in southeast Florida. He lectures both nationally and internationally, emphasizing Familial Hypercholesterolemia, ASCVD prevention, lipid disorders and evolving therapies, Integrative Cardiology, sex distinctions in CVD, and omega-3 fatty acids.